中国医院用药评价与分析2024，Vol.24Issue(7)：893-896,4.DOI:10.14009/j.issn.1672-2124.2024.07.027
奥妥珠单抗相关不良反应的防治研究
Prevention and Treatment of Obinutuzumab Related Adverse Drug Reactions
摘要
Abstract
Obinutuzumab is the first humanized,glycosylation-modified type Ⅱ anti-CD20 monoclonal antibody in the world.Compared with rituximab(type Ⅰ anti-CD20 monoclonal antibody),obinutuzumab is more effective in the treatment of follicular lymphoma.Clinical trial data have shown a higher incidence of adverse drug reactions related to infusion reactions,thrombocytopenia and neutropenia with the use of otuzumab in the Chinese population.This thesis systematically reviews the common types,mechanisms of related adverse drug reactions,preventive measures and black box warnings of obinutuzumab related adverse drug reactions,with the aim of providing relevant references for safe medication in the real world.关键词
奥妥珠单抗/CD20/不良反应/预防/治疗Key words
Obinutuzumab/CD20/Adverse drug reactions/Prevention/Treatment分类
医药卫生引用本文复制引用
李岩,闫雨婷,陈佳,李轶,谢诚,朱建国,夏凡..奥妥珠单抗相关不良反应的防治研究[J].中国医院用药评价与分析,2024,24(7):893-896,4.基金项目
中国研究型医院学会药物评价专委会临床重点药品的使用监测和评价研究专项课题(No.Y2022FH-YWPJ01-102) （No.Y2022FH-YWPJ01-102）
